Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma
Purpose: Interleukin-6 is important for the growth and survival of myeloma cells. This study evaluated blocking IL-6 with siltuximab to delay the transition from high-risk smoldering (SMM) to multiple myeloma (MM). Experimental Design: In a randomized, double-blind, placebo-controlled, multicenter s...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 19, 2019
|
| In: |
Clinical cancer research
Year: 2019, Jahrgang: 25, Heft: 13, Pages: 3772-3775 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-18-3470 |
| Online-Zugang: | Verlag, Pay-per-use, Volltext: http://dx.doi.org/10.1158/1078-0432.CCR-18-3470 Verlag, Pay-per-use, Volltext: https://clincancerres.aacrjournals.org/content/early/2019/03/19/1078-0432.CCR-18-3470 
|
| Verfasserangaben: | Timothy A. Brighton, Amit Khot, Simon J. Harrison, David Ghez, Brendan M. Weiss, Andreas Kirsch, Hila Magen, Mercedes Gironella, Albert Oriol, Matthew Streetly, Britte Kranenburg, Xiang Qin, Rajesh Bandekhar, Peter Hu, Mary Guilfoyle, Ming Qi, Sepideh Nemat, Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1672818400 | ||
| 003 | DE-627 | ||
| 005 | 20230428040107.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190830s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-18-3470 |2 doi | |
| 035 | |a (DE-627)1672818400 | ||
| 035 | |a (DE-599)KXP1672818400 | ||
| 035 | |a (OCoLC)1341238805 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Brighton, Timothy |e VerfasserIn |0 (DE-588)1193741769 |0 (DE-627)1672819075 |4 aut | |
| 245 | 1 | 0 | |a Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma |c Timothy A. Brighton, Amit Khot, Simon J. Harrison, David Ghez, Brendan M. Weiss, Andreas Kirsch, Hila Magen, Mercedes Gironella, Albert Oriol, Matthew Streetly, Britte Kranenburg, Xiang Qin, Rajesh Bandekhar, Peter Hu, Mary Guilfoyle, Ming Qi, Sepideh Nemat, Hartmut Goldschmidt |
| 264 | 1 | |c March 19, 2019 | |
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.08.2019 | ||
| 520 | |a Purpose: Interleukin-6 is important for the growth and survival of myeloma cells. This study evaluated blocking IL-6 with siltuximab to delay the transition from high-risk smoldering (SMM) to multiple myeloma (MM). Experimental Design: In a randomized, double-blind, placebo-controlled, multicenter study, 85 patients with high-risk SMM were randomized to 15 mg/kg siltuximab (43 patients) or placebo (42 patients). The primary endpoint was 1-year PFS rate, based on IMWG CRAB criteria. Secondary endpoints included progressive disease indicator rate, PFS and safety. Results: Median age was 62 years (range: 21-84); 57% were male and 87% had a baseline ECOG score of 0. The 1-year PFS rate was 84.5% (siltuximab) and 74.4% (placebo). After a median follow-up of 29.2 months, 32.6% of PFS events occurred with siltuximab and 42.9% with placebo. Median PFS was not reached with siltuximab but was 23.5 months with placebo [HR 0.50 (95% CI: 0.24,1.04), p=0.0597]. The safety profile of siltuximab was comparable to placebo. Most AEs in the siltuximab group were Grade 2/3, most common SAEs were infections/infestations, and renal/urinary disorders. Mortality (3-siltuximab, 4-placebo) was low in both groups. Conclusions: Although this study did not meet the prespecified protocol hypothesis criteria, data suggest that siltuximab may delay the progression of high-risk SMM. | ||
| 700 | 1 | |a Khot, Amit |e VerfasserIn |4 aut | |
| 700 | 1 | |a Harrison, Simon J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ghez, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weiss, Brendan M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kirsch, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Magen, Hila |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gironella, Mercedes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oriol, Albert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Streetly, Matthew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kranenburg, Britte |e VerfasserIn |4 aut | |
| 700 | 1 | |a Qin, Xiang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bandekhar, Rajesh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hu, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Guilfoyle, Mary |e VerfasserIn |4 aut | |
| 700 | 1 | |a Qi, Ming |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nemat, Sepideh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 25(2019), 13, Seite 3772-3775 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g number:13 |g pages:3772-3775 |g extent:4 |a Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-18-3470 |x Verlag |x Resolving-System |z Pay-per-use |3 Volltext |
| 856 | 4 | 0 | |u https://clincancerres.aacrjournals.org/content/early/2019/03/19/1078-0432.CCR-18-3470 |x Verlag |z Pay-per-use |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190830 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 18 |y j | ||
| 999 | |a KXP-PPN1672818400 |e 3509861310 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"March 19, 2019"}],"note":["Gesehen am 30.08.2019"],"title":[{"title_sort":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma","title":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma"}],"id":{"eki":["1672818400"],"doi":["10.1158/1078-0432.CCR-18-3470"]},"relHost":[{"part":{"volume":"25","extent":"4","pages":"3772-3775","year":"2019","issue":"13","text":"25(2019), 13, Seite 3772-3775"},"language":["eng"],"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"id":{"issn":["1557-3265"],"zdb":["2036787-9"],"eki":["325489971"]},"recId":"325489971","name":{"displayForm":["American Association for Cancer Research"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myelomaClinical cancer research","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"pubHistory":["1.1995 -"],"origin":[{"dateIssuedDisp":"1995-","dateIssuedKey":"1995","publisher":"AACR","publisherPlace":"Philadelphia, Pa. [u.a.]"}],"title":[{"title":"Clinical cancer research","title_sort":"Clinical cancer research"}]}],"recId":"1672818400","name":{"displayForm":["Timothy A. Brighton, Amit Khot, Simon J. Harrison, David Ghez, Brendan M. Weiss, Andreas Kirsch, Hila Magen, Mercedes Gironella, Albert Oriol, Matthew Streetly, Britte Kranenburg, Xiang Qin, Rajesh Bandekhar, Peter Hu, Mary Guilfoyle, Ming Qi, Sepideh Nemat, Hartmut Goldschmidt"]},"physDesc":[{"extent":"4 S."}],"person":[{"given":"Timothy","role":"aut","family":"Brighton","display":"Brighton, Timothy"},{"given":"Amit","role":"aut","family":"Khot","display":"Khot, Amit"},{"given":"Simon J.","role":"aut","display":"Harrison, Simon J.","family":"Harrison"},{"given":"David","role":"aut","display":"Ghez, David","family":"Ghez"},{"role":"aut","given":"Brendan M.","family":"Weiss","display":"Weiss, Brendan M."},{"given":"Andreas","role":"aut","display":"Kirsch, Andreas","family":"Kirsch"},{"role":"aut","given":"Hila","family":"Magen","display":"Magen, Hila"},{"family":"Gironella","display":"Gironella, Mercedes","given":"Mercedes","role":"aut"},{"display":"Oriol, Albert","family":"Oriol","given":"Albert","role":"aut"},{"family":"Streetly","display":"Streetly, Matthew","role":"aut","given":"Matthew"},{"role":"aut","given":"Britte","display":"Kranenburg, Britte","family":"Kranenburg"},{"role":"aut","given":"Xiang","display":"Qin, Xiang","family":"Qin"},{"display":"Bandekhar, Rajesh","family":"Bandekhar","role":"aut","given":"Rajesh"},{"given":"Peter","role":"aut","display":"Hu, Peter","family":"Hu"},{"given":"Mary","role":"aut","family":"Guilfoyle","display":"Guilfoyle, Mary"},{"family":"Qi","display":"Qi, Ming","role":"aut","given":"Ming"},{"given":"Sepideh","role":"aut","family":"Nemat","display":"Nemat, Sepideh"},{"family":"Goldschmidt","display":"Goldschmidt, Hartmut","role":"aut","given":"Hartmut"}],"language":["eng"]} | ||
| SRT | |a BRIGHTONTIRANDOMIZED1920 | ||